9 Spondyloarthritides in females

Bailliere's clinical rheumatology Pub Date : 1998-11-01 DOI:10.1016/S0950-3579(98)80045-9

MD, PhD Jan Tore Gran (Professor and Head, Department of Rheumatology), MD, PhD Monika Østensen (Professor and Head, Department of Rheumatology)

{"title":"9 Spondyloarthritides in females","authors":"MD, PhD Jan Tore Gran (Professor and Head, Department of Rheumatology), MD, PhD Monika Østensen (Professor and Head, Department of Rheumatology)","doi":"10.1016/S0950-3579(98)80045-9","DOIUrl":null,"url":null,"abstract":"<div><p>Few studies have been performed regarding clinical, radiological and prognostic features of females with spondyloarthropathies other than ankylosing spondylitis (AS). In AS, clinical manifestations appear similar in men and women, whereas radiological features appear more frequent and severe in males. However, no consistent differences in outcome and mortality between men and women have been disclosed.</p><p>Although fetal outcome is not compromised in women with spondyloarthropathy (SpA), the interaction of pregnancy and SpA has been studied in detail only in AS. Spinal disease is unchanged while peripheral arthritis and uveitis are suppressed during childbearing. Due to possible maternal and fetal side-effects, NSAIDs must be discontinued during the last 8 weeks of pregnancy, but during lactation several NSAIDs can be used. Treatment with sulphasalazine is compatible with pregnancy and lactation. Children of AS patients exhibit a slightly increased risk of developing SpA later in life.</p></div>","PeriodicalId":77032,"journal":{"name":"Bailliere's clinical rheumatology","volume":"12 4","pages":"Pages 695-715"},"PeriodicalIF":0.0000,"publicationDate":"1998-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-3579(98)80045-9","citationCount":"35","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bailliere's clinical rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0950357998800459","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 35

Abstract

Few studies have been performed regarding clinical, radiological and prognostic features of females with spondyloarthropathies other than ankylosing spondylitis (AS). In AS, clinical manifestations appear similar in men and women, whereas radiological features appear more frequent and severe in males. However, no consistent differences in outcome and mortality between men and women have been disclosed.

Although fetal outcome is not compromised in women with spondyloarthropathy (SpA), the interaction of pregnancy and SpA has been studied in detail only in AS. Spinal disease is unchanged while peripheral arthritis and uveitis are suppressed during childbearing. Due to possible maternal and fetal side-effects, NSAIDs must be discontinued during the last 8 weeks of pregnancy, but during lactation several NSAIDs can be used. Treatment with sulphasalazine is compatible with pregnancy and lactation. Children of AS patients exhibit a slightly increased risk of developing SpA later in life.

查看原文本刊更多论文

9女性脊椎关节炎

关于强直性脊柱炎(AS)以外的女性脊椎关节病的临床、影像学和预后特征的研究很少。在AS中，男性和女性的临床表现相似，而男性的放射学特征更为频繁和严重。然而，男性和女性在结果和死亡率方面没有一致的差异。尽管患有脊椎关节病(SpA)的女性胎儿结局不受影响，但仅在AS中详细研究了妊娠和SpA的相互作用。脊柱疾病不变，而周围关节炎和葡萄膜炎在生育期间得到抑制。由于可能对母体和胎儿产生副作用，非甾体抗炎药必须在妊娠的最后8周停止使用，但在哺乳期可以使用几种非甾体抗炎药。用磺胺嘧啶治疗与妊娠和哺乳期相容。AS患者的孩子在以后的生活中患SpA的风险略有增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bailliere's clinical rheumatology

自引率

0.00%

发文量